Microbiota manipulation to increase macrophage IL-10 improves colitis and limits colitis-associated colorectal cancer. Academic Article uri icon

Overview

abstract

  • Inflammatory bowel disease (IBD) is a chronic life-long inflammatory disease affecting almost 2 million Americans. Although new biologic therapies have been developed, the standard medical treatment fails to selectively control the dysregulated immune pathways involved in chronic colonic inflammation. Further, IBD patients with uncontrolled colonic inflammation are at a higher risk for developing colorectal cancer (CRC). Intestinal microbes can impact many immune functions, and here we asked if they could be used to improve intestinal inflammation. By utilizing an intestinal adherent E. coli that we find increases IL-10 producing macrophages, we were able to limit intestinal inflammation and restrict tumor formation. Macrophage IL-10 along with IL-10 signaling to the intestinal epithelium were required for protection in both inflammation and tumor development. Our work highlights that administration of immune modulating microbes can improve intestinal outcomes by altering tissue inflammation.

publication date

  • January 1, 2022

Research

keywords

  • Colitis
  • Colitis-Associated Neoplasms
  • Gastrointestinal Microbiome
  • Inflammatory Bowel Diseases
  • Microbiota

Identity

PubMed Central ID

  • PMC9450902

Scopus Document Identifier

  • 85137225215

Digital Object Identifier (DOI)

  • 10.1136/gutjnl-2015-310187

PubMed ID

  • 36062329

Additional Document Info

volume

  • 14

issue

  • 1